Reports Q3 revenue $96.9M, consensus $93.07M. “Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital management,” said CEO Kevin Thornal. “We are excited about our recent limited market launch of HFX AdaptivAI, the only artificial intelligenceI)-driven technology in spinal cord stimulation, which delivers responsive and personalized pain relief in real time. We anticipate the full market release of HFX AdaptivAI by the end of November,” continued Thornal. “We are also thrilled to receive regulatory approval to now offer our HFX iQ system in CE-marked countries in Europe…we look forward to the limited market release of HFX iQ in select regions of Europe in Q4 2024, followed by a full market release in 2025…we remain focused on our strategy to become the leading provider of treatment options with the most diversified, differentiated and innovative product portfolio in the pain management space.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVRO:
- NVRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Nevro announces publication of new data from SCS stimulation study
- Nevro price target lowered to $6 from $6.89 at Citi
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%2C%20consensus%20(81c)%20%7C%20Nasdaq&_biz_n=19&rnd=421899&cdn_o=a&_biz_z=1743723969082)
%2C%20consensus%20(81c)%20%7C%20Nasdaq&rnd=823303&cdn_o=a&_biz_z=1743723969086)